Comparing the current results to its competitors, Repare Therapeutics Inc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 21.75 %, recorded in the same quarter.
May 1, 2025
The Path to Innovation: DCx Biotherapeutics Strategic Leap Forward In a bold maneuver that underscores its commitment to innovative therapies in biomedicine, DCx Biotherapeutics Corporation (DCx) has strategically aligned with Repare Therapeutics Inc. a frontrunner in precision oncology, to accelerate the development of multi-modal antibody-drug conjugates. This significant acquisition involves in-licensing Repare’s highly valued discovery platform, incorporating essential program intellectual properties, and extends to retaining valuable scientific talent and infrastructure.DCx s acquisition is more than a mere transaction; it s a catalytic partnership that integrates innovation and skill, coupled with ...
June 5, 2024
Repare Therapeutics Announces Milestone CAMBRIDGE, Mass. and MONTREAL - Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a pioneering clinical-stage precision oncology company, has reached a significant milestone in the fight against aggressive ovarian cancer. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of lunresertib and camonsertib for treating adult patients suffering from platinum-resistant ovarian cancer characterized by CCNE1 amplification or FBXW7 or PPP2R1A mutations. Understanding Platinum-Resistant Ovarian CancerPlatinum-resistant ovarian cancer refers to cases where the disease recurs or progresses despite treatment with plati...
April 30, 2024
Repare Therapeutics Inc., a leader in clinical-stage precision oncology, in collaboration with Debiopharm, a privately-owned Swiss biopharmaceutical company, have made ground-breaking strides in cancer treatment. Both companies have announced that they have successfully dosed the first patient in Module 4 of the ongoing Phase 1/1b Clinical trial, MYTHIC (NCT04855656.) The announcement marks a milestone in the pursuit for revolutionary cancer treatment methods that hold the promise of establishing tomorrow s standards of care for both cancer and infectious diseases.The MYTHIC trial is a clinical exploration seeking to evaluate the synthetic lethal combination of PKMYT1 and WEE1 inhibitors. Both compounds are ...
Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Repare Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Repare Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
